Brendan L Hagerty1, John Aversa1, Laurence P Diggs2, Dana A Dominguez1, Reed I Ayabe3, Andrew M Blakely1, Jeremy L Davis1, Carrie Luu4, Jonathan M Hernandez5. 1. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD. 2. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD; SSM Health Saint Louis University Hospital, St. Louis, MO. 3. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD; Department of Surgery, Harbor UCLA Medical Center, Torrance, CA. 4. SSM Health Saint Louis University Hospital, St. Louis, MO. 5. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD. Electronic address: jonathan.hernandez@nih.gov.
Abstract
BACKGROUND: Alveolar soft part sarcoma is a rare, histologic subtype of soft tissue sarcoma that remains poorly defined. We aimed to describe patient characteristics and treatment patterns and to examine factors associated with survival for patients with alveolar soft part sarcoma. METHODS: After identifying patients with alveolar soft part sarcoma in the National Cancer Database, we recorded their clinicopathologic characteristics. Univariable log-rank survival analysis and Cox proportional hazards model were employed. For context, survival comparisons were included for patients with other sarcoma subtypes. RESULTS: Overall, 293 patients with alveolar soft part sarcoma were identified. Interestingly, patients with head and neck tumors were least likely to present with distant disease (40%, P = .025). The majority of patients underwent resection (n = 183, 63%). Among those, no predictors of lesser survival were identified other than the presence of metastases (hazard ratio 6.04, P ≤ .001). Patients with stage IV alveolar soft part sarcoma who underwent resections experienced improved survival relative to similar patients with more common subtypes of soft tissue sarcomas (P ≤ .001). CONCLUSION: Alveolar soft part sarcoma is exceedingly rare, and patients often present with metastases. Primary tumors can occur anywhere in the body, and location impacts the rates of metastases at presentation. Resection is associated with a favorable survival advantage when compared to other, more common histologic subtypes of soft tissue sarcomas. Published by Elsevier Inc.
BACKGROUND: Alveolar soft part sarcoma is a rare, histologic subtype of soft tissue sarcoma that remains poorly defined. We aimed to describe patient characteristics and treatment patterns and to examine factors associated with survival for patients with alveolar soft part sarcoma. METHODS: After identifying patients with alveolar soft part sarcoma in the National Cancer Database, we recorded their clinicopathologic characteristics. Univariable log-rank survival analysis and Cox proportional hazards model were employed. For context, survival comparisons were included for patients with other sarcoma subtypes. RESULTS: Overall, 293 patients with alveolar soft part sarcoma were identified. Interestingly, patients with head and neck tumors were least likely to present with distant disease (40%, P = .025). The majority of patients underwent resection (n = 183, 63%). Among those, no predictors of lesser survival were identified other than the presence of metastases (hazard ratio 6.04, P ≤ .001). Patients with stage IV alveolar soft part sarcoma who underwent resections experienced improved survival relative to similar patients with more common subtypes of soft tissue sarcomas (P ≤ .001). CONCLUSION: Alveolar soft part sarcoma is exceedingly rare, and patients often present with metastases. Primary tumors can occur anywhere in the body, and location impacts the rates of metastases at presentation. Resection is associated with a favorable survival advantage when compared to other, more common histologic subtypes of soft tissue sarcomas. Published by Elsevier Inc.
Authors: Rick L M Haas; Thomas F Delaney; Brian O'Sullivan; Ronald B Keus; Cécile Le Pechoux; Patricia Olmi; Jan-Peter Poulsen; Beatrice Seddon; Dian Wang Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-18 Impact factor: 7.038
Authors: Breelyn A Wilky; Matteo M Trucco; Ty K Subhawong; Vaia Florou; Wungki Park; Deukwoo Kwon; Eric D Wieder; Despina Kolonias; Andrew E Rosenberg; Darcy A Kerr; Efrosyni Sfakianaki; Mark Foley; Jaime R Merchan; Krishna V Komanduri; Jonathan C Trent Journal: Lancet Oncol Date: 2019-05-08 Impact factor: 41.316
Authors: Brian O'Sullivan; Aileen M Davis; Robert Turcotte; Robert Bell; Charles Catton; Pierre Chabot; Jay Wunder; Rita Kandel; Karen Goddard; Anna Sadura; Joseph Pater; Benny Zee Journal: Lancet Date: 2002-06-29 Impact factor: 79.321
Authors: C A Portera ; V Ho; S R Patel; K K Hunt; B W Feig; P M Respondek; A W Yasko; R S Benjamin; R E Pollock; P W Pisters Journal: Cancer Date: 2001-02-01 Impact factor: 6.860
Authors: Shivaani Kummar; Deborah Allen; Anne Monks; Eric C Polley; Curtis D Hose; S Percy Ivy; Ismail B Turkbey; Scott Lawrence; Robert J Kinders; Peter Choyke; Richard Simon; Seth M Steinberg; James H Doroshow; Lee Helman Journal: J Clin Oncol Date: 2013-04-29 Impact factor: 44.544
Authors: Juan C Gutierrez; Eduardo A Perez; Frederick L Moffat; Alan S Livingstone; Dido Franceschi; Leonidas G Koniaris Journal: Ann Surg Date: 2007-06 Impact factor: 12.969